Dimensional Fund Advisors
CRSP icon

Dimensional Fund Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Dimensional Fund Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15M Sell
275,375
-218,843
-44% -$11.5M ﹤0.01% 2157
2026
Q1 		$23.5M Sell
494,218
-412,889
-46% -$21.8M ﹤0.01% 1893
2025
Q4 		$47.6M Buy
907,107
+30,078
+3% +$1.8M 0.01% 1536
2025
Q3 		$56.8M Sell
877,029
-40,683
-4% -$2.34M 0.01% 1445
2025
Q2 		$44.6M Sell
917,712
-19,433
-2% -$752K 0.01% 1564
2025
Q1 		$31.9M Sell
937,145
-10,156
-1% -$431K 0.01% 1715
2024
Q4 		$37.3M Buy
947,301
+122,695
+15% +$5.79M 0.01% 1687
2024
Q3 		$38.7M Sell
824,606
-125,543
-13% -$6.37M 0.01% 1656
2024
Q2 		$51.3M Buy
950,149
+19,094
+2% +$1.1M 0.01% 1452
2024
Q1 		$63.5M Buy
931,055
+151,601
+19% +$10.9M 0.02% 1293
2023
Q4 		$48.8M Sell
779,454
-100,347
-11% -$5.55M 0.01% 1464
2023
Q3 		$39.9M Buy
879,801
+168,530
+24% +$8.7M 0.01% 1494
2023
Q2 		$39.9M Sell
711,271
-48,464
-6% -$2.75M 0.01% 1509
2023
Q1 		$34.4M Buy
+759,735
New +$36.9M 0.01% 1604
2022
Q3 		$42.4M Buy
649,060
+209,134
+48% +$15.2M 0.02% 1363
2022
Q2 		$26.7M Buy
439,926
+199,939
+83% +$11.8M 0.01% 1698
2022
Q1 		$15.1M Sell
239,987
-19,054
-7% -$1.2M ﹤0.01% 2120
2021
Q4 		$19.6M Buy
259,041
+104,371
+67% +$9.12M 0.01% 1998
2021
Q3 		$17.3M Buy
154,670
+8,848
+6% +$1.11M 0.01% 2073
2021
Q2 		$23.6M Buy
145,822
+7,072
+5% +$860K 0.01% 1974
2021
Q1 		$16.9M Buy
138,750
+31,103
+29% +$4.7M 0.01% 2091
2020
Q4 		$16.5M Buy
107,647
+5,990
+6% +$708K 0.01% 2071
2020
Q3 		$8.51M Buy
101,657
+645
+0.6% +$57.2K ﹤0.01% 2268
2020
Q2 		$7.42M Buy
101,012
+12,527
+14% +$732K ﹤0.01% 2319
2020
Q1 		$3.75M Buy
88,485
+41,952
+90% +$2.17M ﹤0.01% 2517
2019
Q4 		$2.83M Buy
+46,533
New +$2.54M ﹤0.01% 2767

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dimensional Fund Advisors's CRSP Position: Q2 2026 in Review

Dimensional Fund Advisors reduced its CRISPR Therapeutics (CRSP) stake by 44% in Q2 2026, selling an estimated $11.5M and leaving 275,375 shares worth $15M. The position accounts for ﹤0.01% of the portfolio, ranked #2157.

Dimensional Fund Advisors first reported a position in CRSP in Q4 2019 and has held it in 26 quarters since. The position peaked at $63.5M in Q1 2024. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Dimensional Fund Advisors held 275,375 shares of CRISPR Therapeutics worth $15M as of Q2 2026.
  • Dimensional Fund Advisors sold 218,843 CRISPR Therapeutics shares in Q2 2026, an estimated $11.5M.
  • CRISPR Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2157 holding.
  • Dimensional Fund Advisors first reported a position in CRISPR Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • Dimensional Fund Advisors's CRISPR Therapeutics position peaked at $63.5M in Q1 2024.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.